ARTICLE | Company News
Bio3 Research, ProtElix Inc. deal
September 22, 2008 7:00 AM UTC
ProtElix received non-exclusive, worldwide rights to Bio3's IP covering high mobility group B1 ( HMGB1), a pro-inflammatory cytokine, for cardiovascular disorders. ProtElix will use its antibody mimic...